Molecules

FAPI-04

Target FAPClass Small molecule (quinoline inhibitor, DOTA chelator)

7ongoing trials
2radiolabelled forms
0approved products
683publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C40H54F2N10O10
Molar mass (g/mol)
872.9
Exact mass (Da)
872.3992
XLogP
-6.8
H-bond donors
4
H-bond acceptors
19
Rotatable bonds
16
Heavy atoms
62
InChIKey
ICWDAESAANBIGG-LJAQVGFWSA-N
PubChem record
CID 138454803 ↗
IUPAC name
2-[4,7-bis(carboxymethyl)-10-[2-[4-[3-[4-[[2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]carbamoyl]quinolin-6-yl]oxypropyl]piperazin-1-yl]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
SMILES
C1CN(CCN1CCCOC2=CC3=C(C=CN=C3C=C2)C(=O)NCC(=O)N4CC(C[C@H]4C#N)(F)F)C(=O)CN5CCN(CCN(CCN(CC5)CC(=O)O)CC(=O)O)CC(=O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[⁶⁸Ga]Ga-FAPI-04 Syntheses and QC ↗Imaging—6Phase 2—
[¹⁸F]AlF-NOTA-FAPI-04 Syntheses and QC ↗Imaging—4Phase 2—

Ongoing trials · 7Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
FAPI-NICM · FAP ligands (FAPI)NCT07878338 · Ischemic heart diseasePhase 2RecruitingPeking Union Medical College Hospital1
FAP ligands (FAPI)NCT07464132 · Heart failure and cardiomyopathiesPhase 2RecruitingPeking Union Medical College Hospital1
FAP ligands (FAPI)NCT04499365 · Solid tumors (multiple indications)Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical University1
FAP ligands (FAPI)NCT05121779 · Inflammatory diseasesPhase 1RecruitingPeking Union Medical College Hospital1
FAP ligands (FAPI)NCT07132645 · NETs and neuroendocrine carcinomas (other)Phase 1RecruitingUniversity of Michigan Rogel Cancer Center1
FAP ligands (FAPI)NCT06653452 · ColorectalNo phaseRecruitingPeking Union Medical College Hospital1
FAP ligands (FAPI)NCT05140746 · Stomach / esophagusNo phaseRecruitingRuijin Hospital1
Other trials listing it among the interventions (comparator, associated scan) · 1
Other PSMA ligandNCT07639801 · Prostate – otherNo phaseNot yet recruitingPeking University Cancer Hospital & Institute0

PublicationsAll publications in PubMed ↗

683 publications in PubMed for the query below; the most recent:

"FAPI-04"[tiab] OR "FAPI04"[tiab]

  1. A (177)Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer Bioorg Chem, 2026
  2. Targeting Imaging Modality in the Diagnosis of Endometriosis: 68 Ga-FAPI-04 PET/CT Clin Nucl Med, 2026
  3. 68 Ga-FAPI-04 PET/CT Detection of Peritoneal Metastases From a Rare Uterine Tumor Resembling Ovarian Sex-cord Tumor Clin Nucl Med, 2026
  4. Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gastric cancer: impact on metastatic detection and stage migration Br J Radiol, 2026
  5. More Prominent 18 F-FDG Uptake Than 68 Ga-FAPI-04 in Nongestational Choriocarcinoma Clin Nucl Med, 2026
  6. [(68)Ga]-FAPI-04 outperforms [(18)F]-FDG in gastric cancer staging: a comparative study using PET/CT and PET/MR Abdom Radiol (NY), 2026
  7. [18F]AlF-NOTA-FAPI-04 PET/CT for Incidental Detection of a Benign Phyllodes Tumor in a Patient With Prior Colon Cancer Clin Nucl Med, 2026
  8. Spirocyclic Reconfiguration of the Piperazine Linker Improves Quinoline-Based FAPI PET Tracer Performance J Med Chem, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

FAPI-04. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fapi-04/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.